What changed from existing technology?
This study uses a special type of CT scan to tell the difference between cancer and infection in lung tumors, which could help doctors take better tissue samples.
This is the first study to use spectral CT parameters to differentiate between tumor and inflammatory tissue in pneumonic-type lung carcinoma lesions.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
election before needle biopsy. Methods: A total of 102 patients with PTLC and 96 patients with pneumonia were retrospectively enrolled in the study between Se
Abstract ↗OpenAlex author affiliations: Philips (Finland), Philips (China)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Spectral CT parameters may help in selecting the optimal target for needle biopsy in pneumonic-type lung carcinoma lesions.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchSpectral computed tomography multi-parameter images for differentiating between tumor tissue and inflammatory tissue in pneumonic-type lung carcinoma lesionsQuantitative Imaging in Medicine and Surgery · Published 2026-08-27 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.